Aktis Oncology

Aktis Oncology is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha- and beta-emitting radioconjugates for solid tumors, anchored by miniprotein-based targeting scaffolds that enable tumor-specific delivery of radioisotopes. Its lead program AKY-2519 is a B7-H3-targeted miniprotein radioconjugate in a Phase 1b trial in metastatic castration-resistant prostate cancer (mCRPC) and other B7-H3-expressing solid tumors, with first-in-human imaging and dosimetry data presented in May 2026 showing robust tumor uptake and limited normal-tissue exposure. Aktis completed its initial public offering in January 2026 and reported cash of $538.5M in Q1 2026, with management guiding that pro forma cash will fund operations into 2029.